UPDATED: Novartis falls short in controversial IPR process as board nixes Gilenya patent

Tracy Staton

The U.S. and Trademark Office's review has dealt its first blow to Big Pharma. The appeal panel nixed a on ' multiple sclerosis blockbuster , handing a win to challenger Torrent Pharmaceuticals–and fellow generics makers Mylan and Apotex, which had filed a separate challenge.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS